A biosimilar switching program announced by the government of the Canadian province of British Columbia that will see patients using a brand biologic switched to a biosimilar within six months has been warmly received by industry.
The government of BC said the program – instigated following a broad stakeholder consultation – was aimed at “improving the sustainability of its PharmaCare program by expanding the use of biosimilars, which will create